Powered by

Myst Therapeutics Appoints Leading Cancer Immunotherapy Experts to Its Scientific Advisory Board

Mar 12, 2020 - Business Wire
Board and Executive Moves

Myst Therapeutics (Myst), a preclinical stage biotechnology company focused on developing selected TIL-based autologous T cell therapy products for cancer, announced the appointment of five leading experts in the areas of immunotherapy, tumor infiltrating lymphocytes, gene therapy, and oncology diagnostics to its Scientific Advisory Board.

"Myst is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said TJ Langer, President and Chief Execu...